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BACKGROUND: The aim of this study was to describe data on epidemiology,
ventilatory management, and outcome of acute respiratory distress syndrome (ARDS)
in immunocompromised patients.
METHODS: We performed a post hoc analysis on the cohort of immunocompromised
patients enrolled in the Large Observational Study to Understand the Global Impact
of Severe Acute Respiratory Failure (LUNG SAFE) study. The LUNG SAFE study was
an international, prospective study including hypoxemic patients in 459 ICUs from 50
countries across 5 continents.
RESULTS: Of 2813 patients with ARDS, 584 (20.8%) were immunocompromised,
38.9% of whom had an unspecified cause. Pneumonia, nonpulmonary sepsis, and
noncardiogenic shock were their most common risk factors for ARDS. Hospital
mortality was higher in immunocompromised than in immunocompetent patients
(52.4% vs 36.2%; p < 0.0001), despite similar severity of ARDS. Decisions regarding
limiting life-sustaining measures were significantly more frequent in
immunocompromised patients (27.1% vs 18.6%; p < 0.0001). Use of noninvasive
ventilation (NIV) as first-line treatment was higher in immunocompromised patients
(20.9% vs 15.9%; p = 0.0048), and immunodeficiency remained independently
associated with the use of NIV after adjustment for confounders. Forty-eight percent
of the patients treated with NIV were intubated, and their mortality was not different
from that of the patients invasively ventilated ab initio.
CONCLUSIONS: Immunosuppression is frequent in patients with ARDS, and
infections are the main risk factors for ARDS in these immunocompromised patients.
Their management differs from that of immunocompetent patients, particularly the
greater use of NIV as first-line ventilation strategy. Compared with immunocompetent
subjects, they have higher mortality regardless of ARDS severity as well as a higher
frequency of limitation of life-sustaining measures. Nonetheless, nearly half of these
patients survive to hospital discharge.
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